@article{cdb53865bca142e38265ffd21483f4d1,
title = "Transplant associated infections—The role of the gastrointestinal microbiota and potential therapeutic options",
abstract = "Infectious complications are common following kidney transplantation and rank in the top five causes of death in patients with allograft function. Over the last 5 years, there has been emerging evidence that changes in the gastrointestinal microbiota following kidney transplantation may play a key role in the pathogenesis of transplant-associated infections. Different factors have emerged which may disrupt the interaction between the gastrointestinal microbiota and the immune system, which may lead to infective complications in kidney transplant recipients. Over the last 5 years, there has been emerging evidence that changes in the gastrointestinal microbiota following kidney transplantation may play a key role in the pathogenesis of transplant-associated infections. This review will discuss the structure and function of the gastrointestinal microbiota, the changes that occur in the gastrointestinal microbiota following kidney transplantation and the factors underpinning these changes, how these changes may lead to transplant-associated infectious complications and potential treatments which may be instituted to mitigate this risk.",
author = "Samuel Chan and Hawley, {Carmel M.} and Campbell, {Katrina L.} and Mark Morrison and Campbell, {Scott B.} and Isbel, {Nicole M.} and Francis, {Ross S.} and Playford, {Elliot G.} and Johnson, {David W.}",
note = "Funding Information: Research (MM) was carried out at the Translational Research Institute (TRI), Woolloongabba, Queensland, 4102, Australia. The Translational Research Institute is supported by a grant from the Australian Government. However, in relation to this specific paper, neither cash funds were provided, nor TRI core facilities were used, to produce the information included in this narrative review. Funding Information: information Australian GovernmentResearch (MM) was carried out at the Translational Research Institute (TRI), Woolloongabba, Queensland, 4102, Australia. The Translational Research Institute is supported by a grant from the Australian Government. However, in relation to this specific paper, neither cash funds were provided, nor TRI core facilities were used, to produce the information included in this narrative review. Funding Information: Samuel Chan is supported by the National Health and Medical Research Council Postgraduate Scholarship, the Microba recipient grant, the Metro South Research Support Scheme and the Royal Australasian College of Physicians Research Excellence award. Dr Chan is a current recipient of the 2018 Sir Gustav Nossal National Health and Medical Research Council Postgraduate Scholarship award. David Johnson has received consultancy fees, research grants, speaker's honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care. He has received consultancy fees from Astra Zeneca and travel sponsorships from Amgen. He is a current recipient of an Australian National Health and Medical Research Council Practitioner Fellowship. Carmel Hawley is the recipient of research grants paid to her institution from Baxter Healthcare and Fresenius Medical Care and from Otsuka, Janssen and GlaxoSmithKLline for trial steering committee activities, paid to her institution. Nicole Isbel has received consultancy fees and speakers honoraria from Alexion Pharmaceuticals, Novo Nordisk and Amgen. The remaining authors have no conflicts of interest to declare. Publisher Copyright: {\textcopyright} 2019 Asian Pacific Society of Nephrology",
year = "2020",
month = jan,
day = "1",
doi = "10.1111/nep.13670",
language = "English",
volume = "25",
pages = "5--13",
journal = "Nephrology",
issn = "1320-5358",
publisher = "Wiley Blackwell (American Society Bone & Mineral Research)",
number = "1",
}